Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Posts Basic Consolidated EPS Of $-3.9588

0

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)managed to report annual basic consolidated EPS of $-3.9588, which was for the year ended2015-12-31.The company reported basic consolidated EPS of $-3.9588 for the quarter ended 2015-12-31.

EPS from continuing operations

If you look at the performance of the company’s continuing operations, you see that EPS generated from such operations was {EPS_BASIC_CONT_OPER:1541}} for the year ended 2015-12-31. As for the quarter ended 2015-12-31, continuing operations produced EPS of $-1.4585.

EPS contribution from parent

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) received of $-3.9588 EPS boost from the parent company for the annual period ended

For the year ended 2015-12-31, the parent of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) contributed EPS of $-3.9588 to the company’s bottom-line. But for the quarter ended 2015-12-31, EPS boost from the parent was cited as $-3.9588.

What About Basic net EPS

The basic net EPS that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reported for the year ended 2015-12-31 stood at $-3.96. For the quarter ended 2015-12-31, the company posted basic net EPS of $-3.96.

What About Consolidated Diluted EPS?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s consolidated diluted EPS for the year ended 2015-12-31 was reported as $-3.9588. For the quarter ended 2015-12-31 the metric was$-3.9588.

Basic diluted EPS

The company managed to register diluted EPS from continuing operation of at $-3.9588 for the yearended 2015-12-31. But diluted EPS from continuing operations for the quarter ended 2015-12-31 came in at $-3.9588.

Net diluted EPS

Net diluted EPS posted by Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for the year ended 2015-12-31 was $-3.96. On quarterly basis, net diluted EPS for the quarter ended 2015-12-31 was reported as $-3.96.

What portion of diluted EPS came from parent?

For the annual period ended 2015-12-31, the parent company of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said that it parent company boosted its diluted EPS by$-3.9588 in the year ended 2015-12-31. For the quarter ended 2015-12-31, the parent company’s contribution to diluted EPS was $-3.9588.

The company reported net basic EPS of $-3.96 for the year ended 2015-12-31 and net basic EPS of $-3.96 for the quarter ended 2015-12-31.

The number of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)’s basic shares outstanding at the end of the annual period ended 2015-12-31 was 36.783. That compares with 36.783 basic shares outstanding for the quarter ended 2015-12-31.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) had 36.783 diluted shares outstanding at the end of the annual period ended 2015-12-31. But for the quarter ended 2015-12-31, diluted outstanding shares were 36.783.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 2 times, 1 visits today)